内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Cardiovasc Diabetol：心脏利钠肽或与利拉鲁肽减重作用有关

2014-05-23 佚名 dxy

心脏利钠肽
关注

利拉鲁肽治疗在改善糖尿病患者血糖控制同时，还伴随着体重减轻，但是，利拉鲁肽减轻体重的潜在机制仍未完全清楚。心脏利钠肽（NPs）可通过增强脂肪细胞的脂解作用，减轻体脂沉积。然而，利拉鲁肽诱导的体重减轻是否与血浆NPs浓度增加有关仍不清楚。 为此，来自天津医科大学附属代谢病医院的于德民教授及其团队进行了一项研究，探讨利拉鲁肽诱导的体重减轻是否与血浆NPs浓度增加有关。该研究结果发表在2014年02月0

利拉鲁肽治疗在改善糖尿病患者血糖控制同时，还伴随着体重减轻，但是，利拉鲁肽减轻体重的潜在机制仍未完全清楚。心脏利钠肽（NPs）可通过增强脂肪细胞的脂解作用，减轻体脂沉积。然而，利拉鲁肽诱导的体重减轻是否与血浆NPs浓度增加有关仍不清楚。

为此，来自天津医科大学附属代谢病医院的于德民教授及其团队进行了一项研究，探讨利拉鲁肽诱导的体重减轻是否与血浆NPs浓度增加有关。该研究结果发表在2014年02月05日的 Cardiovascular diabetology 杂志上，该杂志影响因子为4.21。

该研究中，于德民教授等招募了31例使用二甲双胍和其他口服降血糖药物（除外噻唑烷二酮类药物）治疗的门诊2型糖尿病患者，给予这些患者皮下注射利拉鲁肽治疗12周。利拉鲁肽治疗前后，通过双能X线吸收法（DXA）和腹部CT评估患者的身体组成、腹部内脏脂肪面积（VAT）和皮下脂肪面积。使用商业化ELISA定量分析试剂盒检测患者血浆心房利钠肽（ANP）和B型心室利钠肽（BNP）。

该研究发现，12周利拉鲁肽治疗后，患者的体重、腰围、总脂肪量、瘦体重、体脂百分比、内脏脂肪面积和皮下脂肪面积都较基线明显下降。与此同时，12周利拉鲁肽治疗后，患者血浆心房利钠肽和B型心室利钠肽水平显著增加。患者身体组成的减少与血浆心房利钠肽和B型心室利钠肽水平增加显著相关。

该研究提示，血浆心房利钠肽和B型心室利钠肽水平增加与利拉鲁肽诱导身体组成改变密切相关。于德民教授指出血浆心脏利钠肽水平增加可从一个新的角度解释利拉鲁肽如何减轻体重。

原始出处

Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, Yu DM1.Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.Cardiovasc Diabetol. 2014 Feb 5

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759448, encodeId=467b1e5944836, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 08 03:07:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636871, encodeId=099716368e121, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Aug 14 23:07:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938294, encodeId=dbb519382949a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 21 02:07:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366468, encodeId=e4e313664685d, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun May 25 09:07:00 CST 2014, time=2014-05-25, status=1, ipAttribution=)]
    2014-10-08 智智灵药

    #BET#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1759448, encodeId=467b1e5944836, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 08 03:07:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636871, encodeId=099716368e121, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Aug 14 23:07:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938294, encodeId=dbb519382949a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 21 02:07:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366468, encodeId=e4e313664685d, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun May 25 09:07:00 CST 2014, time=2014-05-25, status=1, ipAttribution=)]
    2014-08-14 ms9608593228839890

    #DIA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1759448, encodeId=467b1e5944836, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 08 03:07:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636871, encodeId=099716368e121, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Aug 14 23:07:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938294, encodeId=dbb519382949a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 21 02:07:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366468, encodeId=e4e313664685d, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun May 25 09:07:00 CST 2014, time=2014-05-25, status=1, ipAttribution=)]
    2014-07-21 quxin068

    #ASC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1759448, encodeId=467b1e5944836, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 08 03:07:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636871, encodeId=099716368e121, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Aug 14 23:07:00 CST 2014, time=2014-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938294, encodeId=dbb519382949a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 21 02:07:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366468, encodeId=e4e313664685d, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun May 25 09:07:00 CST 2014, time=2014-05-25, status=1, ipAttribution=)]
    2014-05-25 tonychen21

    #利钠肽#

    0